2017
The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer
Pomerantz M, Spisák S, Jia L, Cronin A, Csabai I, Ledet E, Sartor A, Rainville I, O'Connor E, Herbert Z, Szállási Z, Oh W, Kantoff P, Garber J, Schrag D, Kibel A, Freedman M. The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer. Cancer 2017, 123: 3532-3539. PMID: 28608931, PMCID: PMC5802871, DOI: 10.1002/cncr.30808.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCancer Care FacilitiesCarboplatinCohort StudiesDisease-Free SurvivalDrug Resistance, NeoplasmGenes, BRCA2Genetic Predisposition to DiseaseGerm-Line MutationHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingPrognosisProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRetrospective StudiesSurvival AnalysisTaxoidsConceptsCarboplatin-based chemotherapySensitivity to platinum-based chemotherapyMetastatic prostate cancerPlatinum-based chemotherapyProstate cancerBRCA2 variantsProstate-specific antigen declines >Castration-resistant prostate cancerProstate cancer cell linesBRCA2 germline variantsBRCA2 mutation statusCastration-resistant diseasePresence of pathogenic germline mutationsSingle-institution cohortProstate-specific antigenDose of carboplatinDana-Farber Cancer InstituteFisher's exact testPathogenic germline mutationsConsented to analysisCohort of menP-value <BRCA2 carriersBRCA2-associatedCastration-resistant
2007
Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer
Nakabayashi M, Ling J, Xie W, Regan M, Oh W. Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. The Cancer Journal 2007, 13: 125-129. PMID: 17476141, DOI: 10.1097/ppo.0b013e3180465940.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerSecond-line chemotherapyTreated with vinorelbineProstate cancerManagement of hormone-refractory prostate cancerProstate-specific antigen declines >Efficacy of vinorelbineMedian overall survivalResponse to vinorelbineSingle-agent vinorelbineCombination of vinorelbineEffect of vinorelbineProstate-specific antigenPatient baseline characteristicsReversible adverse effectsMedian survivalOverall survivalMedian durationPerformance statusChemotherapeutic managementBaseline characteristicsLonger survivalVinorelbineEstramustineChemotherapy
2006
Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer
Nakabayashi M, Xie W, Regan M, Jackman D, Kantoff P, Oh W. Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer. Cancer 2006, 107: 975-981. PMID: 16862573, DOI: 10.1002/cncr.22085.Peer-Reviewed Original ResearchConceptsAndrogen-independent prostate cancerHigh-dose ketoconazoleLow-dose ketoconazoleSecondary hormonal therapyProstate-specific antigenDose escalationHormone therapyProstate cancerMedian time to disease progressionProstate-specific antigen declines >PSA response ratePrimary androgen deprivation therapyTime to disease progressionAndrogen deprivation therapySevere adverse eventsReversible adverse effectsConcomitant steroidsDeprivation therapyAdverse eventsDisease progressionTherapyGrade 1PatientsResponse rateDose
2005
A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma
Rosenberg J, Galsky M, Rohs N, Weinberg V, Oh W, Kelly W, Small E. A retrospective evaluation of second‐line chemotherapy response in hormone‐refractory prostate carcinoma. Cancer 2005, 106: 58-62. PMID: 16329138, DOI: 10.1002/cncr.21559.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaProstate-specific antigenPSA decline >Clinical cross-resistanceTaxane chemotherapyProstate carcinomaProstate-specific antigen declines >PSA responseResponse to second-lineTime to PSA progressionRandomized phase II trialTaxane-resistant cell linesTaxane-based therapyFirst-line therapyKaplan-Meier methodIxabepilone treatmentPSA declinePSA progressionTaxane therapyMedian survivalSecond-lineChemotherapy responseIxabepiloneDisease progressionRetrospective evaluation
2004
Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer
Oh W, Kantoff P, Weinberg V, Jones G, Rini B, Derynck M, Bok R, Smith M, Bubley G, Rosen R, DiPaola R, Small E. Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer. Journal Of Clinical Oncology 2004, 22: 3705-3712. PMID: 15289492, DOI: 10.1200/jco.2004.10.195.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAndrogensAnticoagulantsAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicComplementary TherapiesCross-Over StudiesDiethylstilbestrolDisease ProgressionDrug ContaminationDrugs, Chinese HerbalEstradiol CongenersEthinyl EstradiolHumansMaleMiddle AgedProspective StudiesProstatic NeoplasmsReproducibility of ResultsTreatment OutcomeWarfarinConceptsAndrogen-independent prostate cancerPC-SPESProstate cancerEthinyl estradiolProstate-specific antigen declines >Prostate-specific antigen progressionMedian time to progressionRandomized phase II studyRandomized phase II trialMedian response durationTime to progressionIndependent prostate cancerPhase II studyPhase II trialCross-over phaseDES armProphylactic warfarinCross-over designII trialII studyThromboembolic eventsResponse durationClinical trialsPatientsDiethylstilbestrol
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply